Key result
Combination therapy of warfarin and aspirin in patients with giant coronary aneurysms caused by Kawasaki disease resulted in a 91% cardiac-event-free survival rate at 10 years.
Why the study?
Does combined oral warfarin and aspirin prevent cardiac events in patients with giant coronary aneurysms caused by Kawasaki disease?
Cohort (n=83)
Yes
Does combined oral warfarin and aspirin prevent cardiac events in patients with giant coronary aneurysms caused by Kawasaki disease?
Combination therapy with warfarin and aspirin in patients with giant coronary aneurysms from Kawasaki disease is associated with high long-term cardiac-event-free survival, though with a known risk of bleeding.
No takes yet. Share an insight, caveat, or question.
May inform antithrombotic choices for giant aneurysms in Kawasaki disease; leaves open need for randomized confirmation of benefit.
Suda et al. (2009) conducted a cohort in Giant coronary aneurysms caused by Kawasaki disease (n=83). Warfarin and aspirin combination therapy was evaluated on Cardiac-event-free survival at 10 years. Combination therapy of warfarin and aspirin in patients with giant coronary aneurysms caused by Kawasaki disease resulted in a 91% cardiac-event-free survival rate at 10 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: